These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

410 related articles for article (PubMed ID: 24590270)

  • 1. Quantitative metabolome analysis profiles activation of glutaminolysis in glioma with IDH1 mutation.
    Ohka F; Ito M; Ranjit M; Senga T; Motomura A; Motomura K; Saito K; Kato K; Kato Y; Wakabayashi T; Soga T; Natsume A
    Tumour Biol; 2014 Jun; 35(6):5911-20. PubMed ID: 24590270
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Isocitrate dehydrogenase 1 mutant R132H sensitizes glioma cells to BCNU-induced oxidative stress and cell death.
    Mohrenz IV; Antonietti P; Pusch S; Capper D; Balss J; Voigt S; Weissert S; Mukrowsky A; Frank J; Senft C; Seifert V; von Deimling A; Kögel D
    Apoptosis; 2013 Nov; 18(11):1416-1425. PubMed ID: 23801081
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Mutant IDH1 Enhances Temozolomide Sensitivity via Regulation of the ATM/CHK2 Pathway in Glioma.
    Lin L; Cai J; Tan Z; Meng X; Li R; Li Y; Jiang C
    Cancer Res Treat; 2021 Apr; 53(2):367-377. PubMed ID: 33070553
    [TBL] [Abstract][Full Text] [Related]  

  • 4. IDH1 R132H mutation regulates glioma chemosensitivity through Nrf2 pathway.
    Li K; Ouyang L; He M; Luo M; Cai W; Tu Y; Pi R; Liu A
    Oncotarget; 2017 Apr; 8(17):28865-28879. PubMed ID: 28427200
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Inhibition of glutaminase preferentially slows growth of glioma cells with mutant IDH1.
    Seltzer MJ; Bennett BD; Joshi AD; Gao P; Thomas AG; Ferraris DV; Tsukamoto T; Rojas CJ; Slusher BS; Rabinowitz JD; Dang CV; Riggins GJ
    Cancer Res; 2010 Nov; 70(22):8981-7. PubMed ID: 21045145
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Adaptive Evolution of the GDH2 Allosteric Domain Promotes Gliomagenesis by Resolving IDH1
    Waitkus MS; Pirozzi CJ; Moure CJ; Diplas BH; Hansen LJ; Carpenter AB; Yang R; Wang Z; Ingram BO; Karoly ED; Mohney RP; Spasojevic I; McLendon RE; Friedman HS; He Y; Bigner DD; Yan H
    Cancer Res; 2018 Jan; 78(1):36-50. PubMed ID: 29097607
    [TBL] [Abstract][Full Text] [Related]  

  • 7. D-2-Hydroxyglutarate producing neo-enzymatic activity inversely correlates with frequency of the type of isocitrate dehydrogenase 1 mutations found in glioma.
    Pusch S; Schweizer L; Beck AC; Lehmler JM; Weissert S; Balss J; Miller AK; von Deimling A
    Acta Neuropathol Commun; 2014 Feb; 2():19. PubMed ID: 24529257
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Overexpression of isocitrate dehydrogenase mutant proteins renders glioma cells more sensitive to radiation.
    Li S; Chou AP; Chen W; Chen R; Deng Y; Phillips HS; Selfridge J; Zurayk M; Lou JJ; Everson RG; Wu KC; Faull KF; Cloughesy T; Liau LM; Lai A
    Neuro Oncol; 2013 Jan; 15(1):57-68. PubMed ID: 23115158
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Specific monoclonal antibodies against IDH1/2 mutations as diagnostic tools for gliomas.
    Kato Y
    Brain Tumor Pathol; 2015 Jan; 32(1):3-11. PubMed ID: 25324168
    [TBL] [Abstract][Full Text] [Related]  

  • 10. R132H mutation in IDH1 gene reduces proliferation, cell survival and invasion of human glioma by downregulating Wnt/β-catenin signaling.
    Cui D; Ren J; Shi J; Feng L; Wang K; Zeng T; Jin Y; Gao L
    Int J Biochem Cell Biol; 2016 Apr; 73():72-81. PubMed ID: 26860959
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Isocitrate dehydrogenase mutations in gliomas.
    Waitkus MS; Diplas BH; Yan H
    Neuro Oncol; 2016 Jan; 18(1):16-26. PubMed ID: 26188014
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Decreasing GSH and increasing ROS in chemosensitivity gliomas with IDH1 mutation.
    Shi J; Sun B; Shi W; Zuo H; Cui D; Ni L; Chen J
    Tumour Biol; 2015 Feb; 36(2):655-62. PubMed ID: 25283382
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Glutamate Is a Noninvasive Metabolic Biomarker of IDH1-Mutant Glioma Response to Temozolomide Treatment.
    Subramani E; Radoul M; Najac C; Batsios G; Molloy AR; Hong D; Gillespie AM; Santos RD; Viswanath P; Costello JF; Pieper RO; Ronen SM
    Cancer Res; 2020 Nov; 80(22):5098-5108. PubMed ID: 32958546
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Metabolism of glioma and IDH1/IDH2 mutations.
    Rossetto M; Ciccarino P; Boisselier B; Labussiere M; Sanson M
    Rev Neurol (Paris); 2011 Oct; 167(10):699-703. PubMed ID: 21885076
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Differential expression of the TWEAK receptor Fn14 in IDH1 wild-type and mutant gliomas.
    Hersh DS; Peng S; Dancy JG; Galisteo R; Eschbacher JM; Castellani RJ; Heath JE; Legesse T; Kim AJ; Woodworth GF; Tran NL; Winkles JA
    J Neurooncol; 2018 Jun; 138(2):241-250. PubMed ID: 29453678
    [TBL] [Abstract][Full Text] [Related]  

  • 16. A high-sensitive HMab-2 specifically detects IDH1-R132H, the most common IDH mutation in gliomas.
    Fujii Y; Ogasawara S; Oki H; Liu X; Kaneko MK; Takano S; Kato Y
    Biochem Biophys Res Commun; 2015 Oct; 466(4):733-9. PubMed ID: 26381180
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Establishment of a multi-specific monoclonal antibody MsMab-1 recognizing both IDH1 and IDH2 mutations.
    Kato Kaneko M; Ogasawara S; Kato Y
    Tohoku J Exp Med; 2013 Jun; 230(2):103-9. PubMed ID: 23782684
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Diagnostic value of glutamate with 2-hydroxyglutarate in magnetic resonance spectroscopy for IDH1 mutant glioma.
    Nagashima H; Tanaka K; Sasayama T; Irino Y; Sato N; Takeuchi Y; Kyotani K; Mukasa A; Mizukawa K; Sakata J; Yamamoto Y; Hosoda K; Itoh T; Sasaki R; Kohmura E
    Neuro Oncol; 2016 Nov; 18(11):1559-1568. PubMed ID: 27154922
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Detection of 2-hydroxyglutaric acid in vivo by proton magnetic resonance spectroscopy in U87 glioma cells overexpressing isocitrate dehydrogenase-1 mutation.
    Lazovic J; Soto H; Piccioni D; Lou JR; Li S; Mirsadraei L; Yong W; Prins R; Liau LM; Ellingson BM; Cloughesy TF; Lai A; Pope WB
    Neuro Oncol; 2012 Dec; 14(12):1465-72. PubMed ID: 23090985
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Comparative study of IDH1 mutations in gliomas by immunohistochemistry and DNA sequencing.
    Agarwal S; Sharma MC; Jha P; Pathak P; Suri V; Sarkar C; Chosdol K; Suri A; Kale SS; Mahapatra AK; Jha P
    Neuro Oncol; 2013 Jun; 15(6):718-26. PubMed ID: 23486690
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 21.